CDDD11-8
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].
Product Specifications
CAS Number
2241659-94-7
UNSPSC
12352005
Target
CDK; FLT3
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cddd11-8.html
Purity
99.62
Solubility
10 mM in DMSO
Smiles
CC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)N=C1C3=CN=C(C=C4)N3C=C4C5=CC=CC=C5
Molecular Formula
C24H26N6
Molecular Weight
398.50
References & Citations
[1]Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel) . 2022 Feb 22;14 (5) :1113.|[2]Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-61012R-PerCP-TR 20 µL
Glucose 6 phosphate isomerase Recombinant Antibody, PerCP Conjugated
Sign In for Pricing
View Details FAB1448J 0.1 mL
Mouse Monoclonal Alkaline Phosphatase/ALPL Antibody (B4-78) [Janelia Fluor 646]
Sign In for Pricing
View Details